SCHEMBL8986987

SCHEMBL8986987

COC(=O)C(C)(C)CCCCCBr

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
ACLY P53396 1/20 0.37
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
TSHR P16473 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
ACAT1 P24752 1/20 0.34
SOAT1 P35610 1/20 0.34
DGAT1 O75907 1/20 0.33
HTT P42858 1/20 0.33
FFAR1 O14842 1/20 0.33
CPT2 P23786 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CTSK P43235 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9129151 1.00 CYP4F2 (0.46) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL8987098 1.00 CYP4F2 (0.46) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL4650865 0.98 CYP4F2 (0.43) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL4122676 0.92 CYP4F2 (0.40) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL1661232 0.83 DGAT1 (0.38) CYP4F2CYP4A11TSHRDGAT1ELANE
SCHEMBL23971207 0.82 CYP4F2 (0.44) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL14809987 0.82 TSHR (0.52) CYP4F2CYP4A11ACLYTSHRKMT2A
SCHEMBL28738660 0.82 TSHR (0.52) CYP4F2CYP4A11ACLYTSHRKMT2A
SCHEMBL23970490 0.82 CYP4F2 (0.44) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL14891456 0.82 TSHR (0.52) CYP4F2CYP4A11ACLYTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617752-B2 Rapidly metabolized lipid compound BEIJING JITAI LIFE SCIENCES LTD (CN) 2026-05-05 US disclosed
EP-4729507-A1 RAPIDLY-METABOLIZED LIPID COMPOUND Beijing Jitai Life Sciences Ltd (CN) 2026-04-22 EP disclosed
US-20250161482-A1 RAPIDLY METABOLIZED LIPID COMPOUND Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) 2025-05-22 US disclosed
US-20250026713-A1 RAPIDLY METABOLIZED LIPID COMPOUND Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) 2025-01-23 US disclosed
WO-2024255415-A1 RAPIDLY-METABOLIZED LIPID COMPOUND 北京剂泰医药科技有限公司 2024-12-19 WO disclosed
US-20230348361-A1 IONIZABLE LIPID COMPOUNDS METIS TECHBIO CO., LTD. (CN) 2023-11-02 US disclosed
US-20230346702-A1 LIPID NANOPARTICLES METIS TECHBIO CO., LTD. (CN) 2023-11-02 US disclosed
US-20230346702-A1 LIPID NANOPARTICLES METIS TECHBIO CO., LTD. (CN) 2023-11-02 US disclosed
WO-2023207101-A1 IONIZABLE LIPID COMPOUNDS Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) 2023-11-02 WO disclosed
US-20230348361-A1 IONIZABLE LIPID COMPOUNDS METIS TECHBIO CO., LTD. (CN) 2023-11-02 US disclosed
CN-111825546-A Synthesis method of piparidic acid 合肥市梓熤科技贸易有限公司 2020-10-27 CN disclosed
US-5492915-A ANTIINFLAMMATORY AGENTS RHONE-POULENC RORER S.A. (FR) 1996-02-20 US disclosed
US-5366982-A Antiinflammatory agents or antihistamines RHONE-POULENC RORER S.A. (FR) 1994-11-22 US disclosed
EP-0540604-A1 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS Aventis Pharma S.A. (FR) 1993-05-12 EP disclosed
WO-1992001675-A2 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS RHONE-POULENC RORER S.A. (FR) 1992-02-06 WO disclosed
US-4714762-A Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof WARNER-LAMBERT COMPANY (US) 1987-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026713-A1 RAPIDLY METABOLIZED LIPID COMPOUND SLC10A1, NPC1, POLRMT CYP4F2 113/4885CYP4A11 39/4885ACLY 819/4885
US-12617752-B2 Rapidly metabolized lipid compound LDLR, SLC10A1, LRAT CYP4F2 405/4885CYP4A11 45/4885ACLY 966/4885
US-20230348361-A1 IONIZABLE LIPID COMPOUNDS PHOSPHO1, SLC10A1, SLCO4C1 CYP4F2 729/4885CYP4A11 127/4885ACLY 2108/4885
US-20230346702-A1 LIPID NANOPARTICLES ABCB4, NPC1L1, CHMP4B CYP4F2 1701/4885CYP4A11 813/4885ACLY 1055/4885
US-20250161482-A1 RAPIDLY METABOLIZED LIPID COMPOUND NPC1, SLC10A1, POLRMT CYP4F2 173/4885CYP4A11 51/4885ACLY 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.